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Introduction: Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial
infarction (AMI). Biomarkers might help in risk stratification and understanding of pathophysiology. Preliminary data
suggests that patients with CS face a profound increase in the osteocyte-derived hormone fibroblast growth factor
23 (FGF-23), which acts as a negative regulator of serum phosphate levels. The present study aimed to assess the
predictive role of FGF-23 for clinical outcome in a large cohort of CS patients with and without renal dysfunction.
Methods: In the randomized Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial, 600 patients
with CS complicating AMI were assigned to therapy with or without IABP. Our predefined biomarker substudy
included 182 patients. Blood sampling was performed in a standardized procedure at three different time points
(day 1 (day of admission), day 2 and day 3). Differences in outcome of patients with FGF-23 levels < and >median
were compared by log-rank testing. Stepwise logistic regression modeling was performed to identify predictors of
death at 30 days and Cox regression analysis for time to death during the first year.
Results: At all three time points, nonsurvivors had significantly higher FGF-23 levels compared to survivors (P <0.001
for all). Patients with FGF-23 levels above the median (395 RU/mL [interquartile range 102;2,395]) were characterized by
an increased 30-day mortality and 1-year mortality. In multivariable analysis FGF-23 levels remained independent
predictors for 30-day (odds ratio per 10log 1.80, 95% confidence interval (CI) 1.11 to 2.92; P = 0.02) and 1-year mortality
(hazard ratio 1.50, 95% CI 1.11 to 2.04, P = 0.009). After stratifying the patients according to their baseline serum
creatinine levels, the negative prognostic association of increased FGF-23 was only significant in those with serum
creatinine greater than median.
Conclusions: In CS, high levels of FGF-23 are independently related to a poor clinical outcome. However, this prognostic
association appears only to apply in patients with impaired renal function.
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Cardiogenic shock (CS) represents the leading cause of
death in patients hospitalized with acute myocardial in-
farction (AMI) [1-3]. Despite advances in treatment over
the last decades, mortality rates are still approaching
50%. The pathophysiology of CS is characterized by an
activation of neurohormones and inflammatory markers,
which contribute to a vicious spiral resulting in systemic
inflammatory response syndrome and finally leading to
death [4].
Epidemiologic studies indicate that hyperphosphate-
mia is related to cardiovascular morbidity and mortality.
This relationship has first been observed in patients with
chronic kidney disease (CKD), but interestingly, it was
found also in the general population [5]. Fibroblast
growth factor 23 (FGF-23) is a phosphaturic hormone
produced by osteocytes [6]. It acts by reducing phos-
phate absorption in the intestinal tract, increasing renal
phosphate excretion, and lowering renal vitamin D activa-
tion [7]. Furthermore, FGF-23 seems to be upregulated
due to activation of the renin-angiotensin-aldosterone-
system (RAAS) [8], which may explain the high levels of
FGF-23 observed in CS [9]. Serum levels of FGF-23 have
been shown to predict cardiovascular events in patients
with CKD [10,11], in patients with normal renal function
and a prevalent cardiovascular disease [12] and also
among individuals from the general population [13,14].
Very recent evidence suggests that, within the broad
spectrum of cardiovascular diseases, FGF-23 might be a
much stronger predictor of incident heart failure events
rather than of atherosclerotic vascular events, both
among CKD patients, [10,11] and among subjects with a
preserved renal function [15].
This close association between FGF-23 and myocardial
disease was further confirmed in two recent cohort studies
that selectively recruited patients with stable chronic sys-
tolic heart failure, among whom FGF-23 independently
predicted cardiovascular events and total mortality [12,13].
In line, several clinical studies associated FGF-23 with
markers of myocardial damage, namely left ventricular
hypertrophy [16-18] and left ventricular dysfunction
[19]. However, it is still controversial whether these asso-
ciations are causal and whether FGF-23 exerts direct ef-
fects on the cardiovascular system [16,20].
A prior small study found that in patients with AMI
complicated by CS without apparent pre-existing CKD
FGF-23 levels were profoundly increased, showing more
than 10-fold higher FGF-23 levels in patients with CS
compared to patients with stable coronary artery disease
(CAD). Furthermore, increased FGF-23 concentrations
were associated with worse clinical outcome [9]. Not-
ably, FGF-23 levels in patients with uncomplicated AMI
did not differ from those of stable CAD patients [9].
This observed increase in CS patients exceeded by farthe one observed in patients with hyperphosphatemia
due to CKD and thus, seemed to occur largely (if not
completely) independently of the serum phosphate levels
of the patients and suggests that - at least under certain
circumstances - CS may induce elevated FGF-23 levels.
Limitations of this preliminary study were its small sam-
ple size with low numbers of events and that the prog-
nostic role of FGF-23 was not assessed with regard to
renal function.
The present study aimed to further assess the prog-
nostic association of FGF-23 in a larger, better character-
ized population with infarction-related CS included in a
prospective, randomized clinical trial and to investigate
its relationship to renal function.
Methods
Patients and study design
The present study is a predefined substudy of the Intraaor-
tic Balloon Pump in Cardiogenic Shock II trial (IABP-
SHOCK II; ClinicalTrials.gov Identifier: NCT00491036)
comparing the use of intraaortic balloon pump (IABP)
versus no IABP support in patients with CS complicating
AMI. This study did not show a significant difference be-
tween the two groups with respect to short- and long-
term outcome. The design of the trial and its main results
have been published previously [21-23]. In brief, 600 pa-
tients were enrolled in 37 centers in Germany and were
randomized to either IABP support or to control in a 1:1
fashion. CS was defined as hypotension, pulmonary con-
gestion, and signs of end-organ hypoperfusion. Exclusion
criteria were duration of CS >12 hours, cardiopulmonary
resuscitation >30 minutes, severe cerebral deficit, mechan-
ical causes of CS, age >90 years, absolute contraindications
against IABP insertion, shock of other cause, or severe
concomitant disease with life expectancy <6 months. Of
the 600 patients included in the trial, 218 were enrolled at
the University of Leipzig - Heart Center with a prospect-
ively planned serial blood sampling. From 182 of these
patients, blood samples were available for the present
analysis (Figure 1). All patients underwent cardiac
catheterization immediately after hospital admission. In
resuscitated patients, cooling was initiated after percu-
taneous coronary intervention (PCI) and blood sampling.
The study was conducted according to the Declaration of
Helsinki, has been approved by the ethical board of the
medical faculty at the University of Leipzig and all pa-
tients or their legal representatives gave written informed
consent.
Laboratory measurements
Blood samples were collected under standardized condi-
tions at different, predefined time points (day 1 (day of ad-
mission during primary PCI), day 2 and day 3). Samples
were immediately centrifuged at 2,400 g for 10 minutes at
Figure 1 Study flow. FGF-23, fibroblast growth factor 23.
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−80°C until further use. C-terminal FGF-23 was measured
from EDTA-plasma samples by enzyme-linked immuno-
sorbent assay (FGF-23: Immunotopics, San Clemente, CA,
USA; low cutoff value 3 rU/mL, high cutoff value 2,000
rU/mL. Samples with FGF-23 > 2,000 rU/mL were mea-
sured after dilution). Samples were assayed in duplicate.
Plasma levels of creatinine, serum lactate and troponin T
were measured by standard institutional laboratory mea-
surements. For assessment of the association of FGF-23
levels with outcome with respect to renal function, the pa-
tient cohort was divided by the median of baseline serum
creatinine.
Statistical analysis
Categorical data are presented as counts or proportions
with the corresponding percentages and compared bychi2 test. Most continuous variables were not normally
distributed. For reasons of uniformity, summary statis-
tics for all continuous variables are thus presented as
medians with interquartile range (IQR). For comparison
of continuous variables, Student’s t test or Mann–Whitney
test were used, as appropriate. Spearman’s rank correlation
was used to investigate associations between continuous
variables. For outcome analysis, all-cause mortality at
30 days and 1 year was used. Patients were stratified into
two groups according to the median of FGF-23 concentra-
tions at baseline. Log-rank testing was used for outcome
assessment. Stepwise logistic regression modeling for
short-term (30-day) mortality and Cox-regression model-
ing for long-term (1-year) mortality were performed. All
baseline variables with an association (P value <0.1) to
short- or long-term mortality in univariable analysis en-
tered the specific model. To assess the association
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baseline (> vs. < median), patients were stratified in two
groups according to the median of serum creatinine
concentrations at baseline and the odds ratios (ORs)
were assessed separately including the calculation for
interaction. Finally, the diagnostic accuracy of FGF-23
for the prediction of mortality was explored by receiver-
operating-characteristics curve analysis. Comparison of
the area under the curves (AUC) of FGF-23, serum lac-
tate and a combination of both factors by multivariable
logistic regression was performed with c statistics. Statis-
tical analysis was performed using commercially available
software (MedCalc for Windows, version 13.3.1.0; Med-
Calc Software, Ostend, Belgium). A two-tailed P value
<0.05 was considered statistically significant.
Results
The baseline characteristics of patients with FGF-23
concentrations at baseline below and above the median
(median: 395 RU/mL, IQR 102;2,395) are depicted in
Table 1. As compared to patients < median, those with
FGF-23 >median were older, had worse renal function,
higher serum lactate and troponin T concentrations. In
addition, they were more likely to be female, to have
prevalent peripheral artery disease, and/or coronary
triple-vessel disease. Of the 182 CS patients, 73 (40.1%)
died within 30 days and 97 (53.3%) within 1 year.Table 1 Baseline characteristics
Overall
n = 182
Age (years) 71 (58;79)
Male sex, n (%) 126 (69)
Body mass index (kg/m2) 27.3 (24.5;29.4)
Baseline serum creatinine (μmol/L) 117 (95;163)
Baseline serum lactate (mmol/L) 3.7 (2.3;7.1)
Baseline troponin T (μg/L) 0.9 (0.3;2.9)
Heart rate at admission (n/min) 91 (75;110)
Systolic blood pressure at admission (mmHg) 86 (78;106)
Hypertension, n (%) 127 (70)
Hypercholesterolemia, n (%) 55 (30)
Diabetes mellitus, n (%) 65 (36)
Known peripheral artery disease, n (%) 22 (12)
Prior myocardial infarction, n (%) 39 (21)
Prior PCI, n (%) 33 (18)
Prior CABG, n (%) 10 (6)
Randomized to IABP, n (%) 89 (49)
Triple-vessel disease, n (%) 90 (50)
Resuscitation, n (%) 67 (37)
Mechanical ventilation at admission, n (%) 95 (52)
FGF-23: fibroblast growth factor-23; PCI: percutaneous coronary intervention; CABGAssociation of FGF-23 with clinical outcome
Nonsurvivors after 30 days had significantly higher FGF-
23 levels compared to survivors; this difference was even
more accentuated at day 2 and day 3 (Figure 2). In
Kaplan-Meier analysis, patients with baseline FGF-23
levels above the median were characterized by an in-
creased 30-day and 1-year mortality (Figure 3A). A land-
mark analysis in the 30-day survivors showed that a
mortality difference was also found after the acute phase
(Figure 3B). Also FGF-23 levels on day 2 and 3 were pre-
dictive in Kaplan-Meier analysis for short-term (day 2:
hazard ratio (HR) 2.41, 95% confidence interval (CI) 1.29
to 4.49, P = 0.007, day 3: HR 2.89, 95%CI 1.56 to 5.34,
P = 0.001), and long-term mortality (day 2: HR 2.31,
95%CI 1.41 to 3.80, P = 0.001, day 3: HR 3.13, 95%CI
1.91 to 5.14, P <0.001).
Regression analysis
In univariable logistic regression analysis FGF-23, age,
ejection fraction (EF), serum lactate and serum creatin-
ine concentrations showed an association with time to
30-day mortality (P <0.1 for all). In multivariable step-
wise logistic regression analysis including these parame-
ters, FGF-23 concentration remained an independent
predictor of clinical outcome at 30 days (Table 2). In
long-term (1-year) survival analysis including the same
parameters, FGF-23 levels also remained independentFGF-23 <median FGF-23 >median P value
n = 91 n = 91
67 (54;75) 74 (63;81) <0.001
71 (78) 55 (60) 0.02
27.5 (24.7;29.7) 27.1 (24.5;29.4) 0.49
99 (81;123) 147 (109;208) <0.001
3.0 (2.0;5.5) 4.6 (3.1;7.8) <0.001
0.7 (0.2;1.6) 1.2 (0.4;3.4) 0.01
90 (72;110) 98 (78;114) 0.16
85 (79;105) 86 (78;106) 0.98
57 (63) 70 (77) 0.053
22 (24) 33 (36) 0.11
28 (31) 37 (41) 0.22
5 (5) 17 (19) 0.01
20 (22) 19 (21) 0.99
17 (19) 16 (18) 0.99
6 (7) 4 (4) 0.75
51 (56) 38 (42) 0.08
33 (36) 57 (63) <0.001
38 (42) 29 (32) 0.22
45 (49) 50 (55) 0.55
: coronary artery bypass graft; IABP: intraaortic balloon pump.
Figure 2 Levels of FGF-23 on the different time points for 30-day survivors and nonsurvivors. FGF-23: fibroblast growth factor 23.
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FGF-23 per 10LOG: HR 1.50, 95%CI 1.11 to 2.04, P =
0.009, age per 10 years: HR 1.27, 95%CI 1.03 to 1.56,
P = 0.03; EF per 10% increase: HR 0.76, 95%CI 0.62 to
0.92, P = 0.006; serum lactate per 10LOG: HR 2.92, 95%CI
1.23 to 6.94, P = 0.009, coronary three-vessel disease and
baseline serum creatinine, both univariable predictive,
were not significant in multivariable testing).
Receiver operating characteristics
In c statistics, the AUC of FGF-23 levels was equal to
the one of serum lactate concentrations at baseline with
regard to the prediction of 30-day mortality (FGF-23 vs.
serum lactate: 0.677 vs. 0.673; P = 0.95). Interestingly,
when combining both factors, the AUC increased signifi-
cantly compared to the AUC of serum lactate alone
(0.724 vs. 0.673; P = 0.04).
FGF-23 and renal function
Baseline FGF-23 levels correlated moderately with base-
line serum creatinine levels (r = 0.583; P <0.001). Patients
were stratified in two groups according to the medianFigure 3 Kaplan-Meier curves for patients with FGF-23 levels > media
(A) and as landmark analysis for patients surviving until day 30 (B). FGFcreatinine levels at baseline (117 μmol/L). FGF-23 levels
at baseline were significantly higher in patients with
serum creatinine levels > median (low vs. high creatinine:
150 [IQR 69; 485] vs. 1264 [358; 5706] RU/mL, P <0.001).
The difference in FGF-23 concentrations between survi-
vors and nonsurvivors was only evident in the group of
patients with creatinine concentrations above the median
(FGF-23: 626 [IQR 164;3,673] vs. 3,477 [690;9,986] RU/
mL, P <0.001), whereas in the group with creatinine con-
centrations below the median, no differences in FGF-23
levels were observed with respect to the survival of the pa-
tients (141 (72;458) vs. 204 (62;524) RU/mL, P = 0.72). In
accordance, the negative prognostic association of in-
creased baseline FGF-23 with 30-day mortality as well as
1-year mortality was only significant in patients with
serum creatinine above the median, whereas in the group
of patients with creatinine below the median, no difference
was observed (Figure 4A + B). This was also observed for
the adjusted HR for long-term mortality by quartiles of
FGF-23 concentration (Table 3). The calculated inter-
action terms for baseline FGF-23 < and >median with
baseline serum creatinine < and >median in prediction ofn (red dashed line) and <median (blue line) for the overall cohort
-23: fibroblast growth factor 23; HR: hazard ratio; CI: confidence interval.
Table 2 Multivariable stepwise logistic regression analysis for 30-day mortality
Univariable analysis Multivariable stepwise logistic regression analysis
OR 95%CI P OR 95%CI P
FGF-23 per 10LOG 2.08 1.41–3.06 <0.001 1.80 1.11–2.92 0.02
Age per 10 years 1.30 1.02–1.66 0.03 - - -
Ejection fraction per 10% 0.59 0.44–0.80 <0.001 0.63 0.46–0.86 0.003
Diabetes mellitus 1.21 0.65–2.24 0.54
Serum lactate per 10LOG 7.90 2.79–22.42 <0.001 4.18 1.17–14.87 0.03
Serum creatinine per 10LOG 15.35 2.92–80.77 0.001 - - -
Troponin T per 10LOG 1.29 0.80–2.07 0.30
Known peripheral artery disease 1.28 0.52–3.15 0.59
Systolic blood pressure per 10 mmHg 0.93 0.81–1.08 0.33
Randomized to control group 1.13 0.62–2.04 0.69
Female gender 1.46 0.77–2.76 0.25
Three-vessel disease 1.57 0.86–2.85 0.14
Resuscitation prior randomization 1.36 0.74–2.50 0.33
Mechanical ventilation at admission. 1.43 0.79–2.60 0.24
OR: odds ratio; CI: confidence interval; FGF-23: fibroblast growth factor 23.
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significant (Figure 5). When the population was divided
into tertiles by baseline serum creatinine the AUC for the
prognostic value in ROC analysis of baseline FGF-23
increased per tertile (Group 1 (creatinine ≤100 μmol/L):
AUC 0.515; Group 2 (creatinine 101 to 142 μmol/L): AUC
0.675; Group 3 (creatinine ≥142 μmol/L): AUC 0.750).
Discussion
The present study aimed to validate and extend prelim-
inary findings from a prior study on plasma levels of the
phosphaturic hormone FGF-23 in CS: we first confirm
profoundly increased FGF-23 plasma levels in patients
with infarction-related CS in a larger, better-characterized
patient cohort within the randomized IABP-SHOCK II
trial [9]. Second, we were able to show that increased
FGF-23 levels are associated not only with increased
short-time (30-day) - as reported in our earlier study [9] -Figure 4 Kaplan-Meier curves for patients with FGF-23 levels > media
baseline serum creatinine >median (A) and <median (B). FGF-23: fibrobut also long-term (1-year) mortality. Third, the negative
prognostic association of FGF-23 with both short- and
long-time mortality persisted in multivariable analyses ad-
justed for several well-known prognostic factors. Fourth,
the prognostic role of FGF-23 appears only to be relevant
in patients with impaired renal function, as assessed by
the baseline serum creatinine concentrations.
The phosphaturic hormone FGF-23 is profoundly in-
creased in patients with CKD [24] and associated with
cardiovascular events and mortality [10,11]. Recently,
understanding has emerged that this relationship is also
present in apparently healthy individuals from the gen-
eral population [14], in patients with prevalent cardio-
vascular disease [10] and in patients with stable chronic
systolic heart failure [12,13].
As a pathophysiological explanation for these epi-
demiological findings, Faul et al. could show that FGF-
23 exerts direct harmful pro-hypertrophic effects onn (red dashed line) and <median (blue line) for patients with
blast growth factor 23; HR: hazard ratio; CI: confidence interval.
Table 3 Fibroblast growth factor 23 quartiles and hazard
ratios with 95% confidence interval for long-term mortality
adjusted for age, ejection fraction and baseline serum
lactate
Quartile 1 Quartile 2 Quartile 3 Quartile 4








1 0.89 0.95 1.42
(0.33–2.38) (0.36–2.49) (0.30–6.82)
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gether, there is evidence from clinical and experimental
studies that FGF-23 may not only be a bystander, but a
direct or indirect mediator of cardiovascular disease.
However, a direct contribution of FGF-23 to myocardial
disease is still under debate, after two further experi-
mental studies failed to confirm a role of FGF-23 in left
ventricular hypertrophy [20,25].
The present data provide further evidence to the pro-
posed reverse causality between elevated FGF-23 and
cardiovascular disease according to which high FGF-23
secretion (hyperphosphatonism) not (only) induces car-
diovascular disease, but instead prevalent subtle or overt
cardiovascular disease may induce FGF-23 secretion.
This hypothesis is underscored by our present observa-
tions that - as in our previous study [9] - FGF-23 levels
in CS patients exceeded by far those found in patients
with stable CAD, or in individuals with mild-to moder-
ate CKD. Thus, it is unlikely that patients recruited into
the present study had a substantial elevation of FGF-23
before they suffered CS, even though we cannot present
formal evidence for this assumption.
Interestingly, in several prospective epidemiologic stud-
ies, baseline FGF-23 levels did not predict future AMI
[12,26] and in our previous study, patients with AMIFigure 5 Forest plot for odds ratios of FGF-23 levels >median for short
median and <median. FGF-23: fibroblast growth factor 23; OR: odds ratio; Cwithout CS are characterized by FGF-23 levels comparable
to those of stable CAD patients [9]. Thus, the profound
rise in FGF-23 appears to be due to the neuroendocrinolo-
gic and/or hemodynamic impacts of CS rather than to the
acute myocardial ischemia per se. A possible explanation
for the increase in FGF-23 in CS might be the interplay
between FGF-23, the RAAS [8,27] and the sympathetic ac-
tivation [28]. Patients with CS are characterized by an acti-
vated RAAS and sympathetic system [29]. The increased
RAAS activity downregulates Klotho, an important cofac-
tor of FGF-23 signaling, and leads to an upregulation of
FGF-23 [8]. Similarly, a role of sympathetic activation in
FGF-23 secretion was proposed [28].
In the present study, the negative prognostic associ-
ation of FGF-23 was not only observed with regard to
short-term (30 days) but also to 1-year mortality. Fur-
thermore, FGF-23 remained an independent predictor
for mortality in a multivariate analysis including several
factors known to affect risk of CS patients. Notably, re-
garding risk prediction of short-term mortality, FGF-23
was equally potent as serum lactate levels and combin-
ation of these two factors increased the diagnostic accur-
acy significantly.
Interestingly, the negative prognostic association of
FGF-23 was only observed in the patients with serum
creatinine concentrations at baseline above the median,
whereas in patients below the median, FGF-23 levels did
not differ between survivors and nonsurvivors. These re-
sults are in line with previously published epidemiologic
data, where associations to left ventricular hypertrophy
and outcome have generally been stronger among indi-
viduals with impaired renal function [18,30]. As one ex-
ample, cross-sectional data from the Heart and Soul
Study, which recruited 887 patients with stable CAD
and history of AMI, found an association between FGF-
23 and left ventricular hypertrophy in individuals with
estimated glomerular filtration rate <60 ml/min/1.73 m2,
but not in participants with intact renal function [20].- and long-term survival grouped by baseline serum creatinine >
I: confidence interval.
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vitamin D deficiency due to reduced 1α-hydroxylase ac-
tivity. Low vitamin D has been shown to be a predictor
of mortality in critically ill patients [31,32]. As vitamin D
inhibits renin release, vitamin D deficiency is believed to
increase RAAS activity. This, in turn, might further pro-
mote the previously mentioned negative interplay be-
tween the RAAS and FGF-23 in CS. Increased RAAS
activity leads to increased FGF-23 levels, which, in turn
further impairs vitamin D activation [8].
As a limitation to all epidemiologic studies, we cannot
prove that elevated FGF-23 is causally linked to adverse
outcome in CS. One potential mechanism might be the
above-mentioned interplay between FGF-23 and vitamin
D. Moreover, recent evidence suggests that FGF-23 may
contribute to volume retention, which further aggravates
CS [33]. Alternatively, high FGF-23 may reflect preexist-
ing CKD, or more severe left ventricular disease, both of
which directly contribute to poor outcome in CS. A fur-
ther limitation of the study is its design as a single-
center subanalysis of a multicenter study.
Conclusions
In conclusion, our findings confirm in a large cohort
study that patients with CS are characterized by pro-
foundly increased FGF-23 levels. Beyond this, we show
that in CS patients increased FGF-23 has a strong and
independent negative prognostic association with short-
and long-term outcome and that this association is ob-
served only in patients with worse renal function. These
results underline the need for future studies in order to
clarify whether this association is causal or whether
FGF-23 rather represents an innocent bystander, partly
reflecting the underlying kidney damage, or more severe
left ventricular disease.
Key messages
 FGF-23 levels are an independent predictor of short-
and long-term outcome in CS complicating AMI.
 These findings were only observed in patients with
reduced kidney function.
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